

**Mouse Insr Antibody (P1325)**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP21619a**

## Specification

---

### Mouse Insr Antibody (P1325) - Product Information

Application	WB,E
Primary Accession	<a href="#">P15208</a>
Reactivity	Mouse
Host	Rabbit
Clonality	polyclonal
Isotype	Rabbit IgG

### Mouse Insr Antibody (P1325) - Additional Information

**Gene ID** 16337

#### Other Names

Insulin receptor, IR, CD220, Insulin receptor subunit alpha, Insulin receptor subunit beta, Insr

#### Target/Specificity

This Mouse Insr antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 1325-1358 amino acids from Mouse Insr.

#### Dilution

WB~~1:2000

#### Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

#### Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

#### Precautions

Mouse Insr Antibody (P1325) is for research use only and not for use in diagnostic or therapeutic procedures.

### Mouse Insr Antibody (P1325) - Protein Information

#### Name Insr

**Function** Receptor tyrosine kinase which mediates the pleiotropic actions of insulin (PubMed:[38061240](#)). Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different

phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras- MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin- stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGF1 and IGFII). When present in a hybrid receptor with IGF1R, binds IGF1 (By similarity). In adipocytes, inhibits lipolysis (PubMed:[27322061](#)).

#### Cellular Location


Cell membrane; Single-pass type I membrane protein. Recycling endosome membrane. Late endosome. Lysosome Note=Binding of insulin to INSR induces internalization and lysosomal degradation of the receptor, a means for down-regulating this signaling pathway after stimulation. In the presence of SORL1, internalized INSR molecules are redirected back to the cell surface, thereby preventing their lysosomal catabolism and strengthening insulin signal reception


#### Mouse Insr Antibody (P1325) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### Mouse Insr Antibody (P1325) - Images






All lanes : Anti-Insr Antibody (P1325) at 1:2000 dilution Lane 1: mouse heart lysate Lane 2: mouse liver lysate Lane 3: NIH/3T3 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 156 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



All lanes : Anti-Insr Antibody (P1325) at 1:2000 dilution Lane 1: L6 whole cell lysate Lane 2: mouse heart lysate Lane 3: mouse liver lysate Lane 4: NIH/3T3 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 156 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



Anti-Insr Antibody (P1325) at 1:2000 dilution + mouse kidney lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 156 kDa Blocking/Dilution buffer: 5% NFD/MTBST.

### Mouse Insr Antibody (P1325) - Background

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src- homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti- apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K- AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). When present in a hybrid receptor with IGF1R, binds IGF1 (By similarity).

### Mouse Insr Antibody (P1325) - References

Flores-Riveros J.R., et al. *J. Biol. Chem.* 264:21557-21572(1989).  
Church D.M., et al. *PLoS Biol.* 7:E1000112-E1000112(2009).  
Sibley E., et al. *Proc. Natl. Acad. Sci. U.S.A.* 86:9732-9736(1989).  
Sawka-Verhelle D., et al. *J. Biol. Chem.* 271:5980-5983(1996).  
Ribon V., et al. *Mol. Cell. Biol.* 18:872-879(1998).

